BTIG Maintains Sell Rating for Talis Biomedical: Here's What You Need To Know

BTIG has decided to maintain its Sell rating of Talis Biomedical TLIS and raise its price target from $0.35 to $5.00.

Shares of Talis Biomedical are trading down 4.35% over the last 24 hours, at $6.81 per share.

A move to $5.00 would account for a 26.58% decrease from the current share price.

About Talis Biomedical

Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.